Phase II, Randomized,Double-Blind, Single Enter, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults.

Trial Profile

Phase II, Randomized,Double-Blind, Single Enter, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs TDENV LAV (Primary)
  • Indications Dengue
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 29 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2011 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 26 Jul 2010 Planned end date (1 Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top